Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Fractyl Health, Inc. (NASDAQ:GUTS) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 1,870,000 shares, a growth of 61.2% from the September 15th total of 1,160,000 shares. Based on an average daily volume of 356,500 shares, the short-interest ratio is currently 5.2 days. Currently, 9.4% of the company’s shares are sold short.

Insider Buying and Selling at Fractyl Health

In other news, insider Jay David Caplan sold 65,000 shares of Fractyl Health stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total transaction of $188,500.00. Following the transaction, the insider now directly owns 30,484 shares of the company’s stock, valued at $88,403.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Investors Weigh In On Fractyl Health

Several institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. bought a new position in shares of Fractyl Health during the first quarter worth about $9,911,000. M28 Capital Management LP bought a new position in shares of Fractyl Health during the 1st quarter worth approximately $13,735,000. Rhumbline Advisers bought a new position in shares of Fractyl Health during the 2nd quarter worth approximately $32,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after purchasing an additional 25,829 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Fractyl Health in the second quarter worth $61,000.

Fractyl Health Price Performance

Shares of NASDAQ GUTS traded down $0.04 during mid-day trading on Monday, reaching $2.42. 145,139 shares of the company’s stock were exchanged, compared to its average volume of 305,168. The company has a current ratio of 7.46, a quick ratio of 7.46 and a debt-to-equity ratio of 0.40. The business has a fifty day simple moving average of $2.69 and a 200 day simple moving average of $4.72. Fractyl Health has a twelve month low of $1.74 and a twelve month high of $14.50.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.10. The company had revenue of $0.04 million during the quarter. As a group, equities research analysts expect that Fractyl Health will post -1.61 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.